Parkinson's Disease/Movement Disorders News

Neuraly has announced that its investigational NLY01 did not meet the primary study endpoint of improvement in motor symptoms in patients with early, untreated Parkinson’s disease.

Biopharmaceutical company Aptinyx reported its drug for cognitive impairment was not efficacious in a phase 2 clinical trial investigating its use in patients with Parkinson’s disease and Lewy body dementia, according to a press release.

Ryne Biotechnology Inc. has announced a $4 million Clinical Stage Research Program grant from the California Institute for Regenerative Medicine to advance its lead candidate for the treatment of Parkinson’s disease.

Athira Pharma Inc. revealed its list of planned clinical trials for 2023, which include development of therapeutics for Alzheimer’s disease, Parkinson’s disease and ALS.

Despite the number of new medications produced to treat a range of neurologic diseases, limited utilization is driven by relatively high cost and similar efficacy to less expensive drugs, according to a study published in Neurology.

Athira Pharma Inc. will proceed in 2023 with several clinical trials for treatments for Alzheimer’s disease, Parkinson’s disease and ALS, the biopharmaceutical company announced in a press release.

An association between common antiepileptic drugs and incident Parkinson’s disease was found, researchers reported in JAMA Neurology.

Individuals with prodromal or unrecognized Parkinson’s disease may have greater impairment involving mobility and strength up to 3 years prior to diagnosis, researchers reported in JAMA Neurology.

The use of machine learning models identified three distinct subtypes of Parkinson’s disease, which “could have immediate implications” in detecting clinical outcomes, researchers reported in NPJ Parkinson’s Disease.

The annual incidence of Parkinson’s disease among adults aged 65 years and older is 50% higher than previous estimates of 60,000 diagnoses annually, researchers reported in NPJ Parkinson’s Disease.